Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Two Arm Bridging Study to Evaluate the Efficacy of Romiplostim in the Treatment of Adult Severe Aplastic Anemia Participants Who Are Either Previously Untreated With IST or Refractory to IST

Next Previous
Trial Profile

Two Arm Bridging Study to Evaluate the Efficacy of Romiplostim in the Treatment of Adult Severe Aplastic Anemia Participants Who Are Either Previously Untreated With IST or Refractory to IST

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Ciclosporin (Primary) ; Romiplostim (Primary)
  • Indications Aplastic anaemia
  • Focus Therapeutic Use
  • Sponsors Amgen

Most Recent Events

  • 28 Sep 2023 Planned End Date changed from 22 Mar 2025 to 25 Feb 2025.
  • 28 Sep 2023 Planned primary completion date changed from 22 Mar 2025 to 25 Feb 2025.
  • 28 Sep 2023 Planned initiation date changed from 25 Sep 2023 to 31 Aug 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top